written on 28.05.2014

Cancer drugs beware: Docs to get monthly paybacks for sticking to preferred meds


Payers have decided that formularies aren&#39;t enough, at least for cancer drugs. As the&nbsp;<em>Wall Street Journal</em>&nbsp;reports, insurers are revamping their reimbursement protocols to strip incentives for pricey meds–and introduce new ones for &quot;preferred&quot; treatments.